ArticleFrontiers in immunology2023

NR2F6, a new immune checkpoint that acts as a potential biomarker of immunosuppression and contributes to poor clinical outcome in human glioma.

Hayat Miftah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.